Phase I trial of vandetanib and oral etoposide (VP-16) for recurrent malignant gliomas (MG).

被引：1
|
作者：
Brickhouse, A. [1 ]
Vredenburgh, J. J. [1 ]
Gururangan, S. [1 ]
Reardon, D. A. [1 ]
Desjardins, A. [1 ]
Peters, K. [1 ]
Herndon, J. E. [1 ]
Norfleet, J. [1 ]
Marcello, J. [1 ]
Friedman, H. S. [1 ]
机构：
[1] Duke Univ, Med Ctr, Durham, NC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.2038
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2038
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Clinical trial of CPT-11 and VM-26/VP-16 for patients with recurrent malignant brain tumors
    Lynn G. Feun
    Angela Marini
    Howard Landy
    Arnold Markoe
    Deborah Heros
    Carlos Robles
    Cristina Herrera
    Niramol Savaraj
    Journal of Neuro-Oncology, 2007, 82 : 177 - 181
  • [42] Clinical trial of CPT-11 and VM-26/VP-16 for patients with recurrent malignant brain tumors
    Feun, Lynn G.
    Marini, Angela
    Landy, Howard
    Markoe, Arnold
    Heros, Deborah
    Robles, Carlos
    Herrera, Cristina
    Savaraj, Niramol
    JOURNAL OF NEURO-ONCOLOGY, 2007, 82 (02) : 177 - 181
  • [43] Pilot trial of the rate of response, safety, and tolerability of temozolomide and oral VP-16 in patients with recurrent or treatment-induced malignant central nervous system tumors
    Terasaki, Mizuhiko
    Bouffet, Eric
    Katsuki, Hiroshi
    Fukushima, Shintaro
    Shigemori, Minoru
    SURGICAL NEUROLOGY, 2008, 69 (01): : 46 - 50
  • [44] A PHASE-II TRIAL OF ORAL VP-16 WITH MITOXANTRONE AND IFOSFAMIDE MESNA FOR SALVAGE OF RELAPSED OR REFRACTORY LYMPHOMA
    ROMAGUERA, JE
    RODRIGUEZ, MA
    HAGEMEISTER, FB
    MCLAUGHLIN, P
    SWAN, F
    SARRIS, AH
    YOUNES, A
    HILL, D
    CABANILLAS, F
    BLOOD, 1993, 82 (10) : A576 - A576
  • [45] Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas
    Peters, Katherine B.
    Lipp, Eric S.
    Miller, Elizabeth
    Herndon, James E., II
    McSherry, Frances
    Desjardins, Annick
    Reardon, David A.
    Friedman, Henry S.
    JOURNAL OF NEURO-ONCOLOGY, 2018, 137 (02) : 349 - 356
  • [46] Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas
    Katherine B. Peters
    Eric S. Lipp
    Elizabeth Miller
    James E. Herndon
    Frances McSherry
    Annick Desjardins
    David A. Reardon
    Henry S. Friedman
    Journal of Neuro-Oncology, 2018, 137 : 349 - 356
  • [47] Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma
    Korones, DN
    Benita-Weiss, M
    Coyle, TE
    Mechtler, L
    Bushunow, P
    Evans, B
    Reardon, DA
    Quinn, JA
    Friedman, H
    CANCER, 2003, 97 (08) : 1963 - 1968
  • [48] PHASE-II TRIAL OF VP-16 IN TREATMENT OF ADVANCED OVARIAN ADENOCARCINOMA
    SLAYTON, R
    PETTY, W
    BLESSING, J
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1979, 20 (MAR): : 190 - 190
  • [49] Phase I Trial of Vandetanib Plus Sirolimus in Adults with Recurrent Glioblastoma
    Chheda, Milan
    Wen, Patrick
    Hochberg, Fred
    Chi, Andrew
    Drappatz, Jan
    Yang, Daniel
    Eichler, April
    Beroukhim, Rameen
    Norden, Andrew
    Gerstner, Elizabeth
    Batchelor, Tracy
    NEUROLOGY, 2012, 78
  • [50] PHASE-II STUDY OF ETOPOSIDE (VP-16) IN THE TREATMENT OF ADVANCED HEAD AND NECK-CANCER
    GRUNBERG, SM
    FELMAN, IE
    GALA, KV
    JOHNSON, KB
    OWENS, JC
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1985, 8 (05): : 393 - 395
12345